Vaxcyte, Inc. PCVX
56.21
(0.69)
(1.21%)
as of 25 Sep
- Market cap
- $8.5B
- P/E
- 0.0×
Follow PCVX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
8.83 | 7.91 | 7.49 | 5.72 |
Net Debt/EBITDA |
7.15 | 5.84 | 5.06 | 4.99 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 0.91 | 0.88 | 0.82 | |
Capex/Depreciation |
(1.30) | (0.38) | (0.77) | (0.91) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.08) | (1.67) | (2.03) | (1.64) | |
Cash per Share |
12.57 | 11.47 | 12.45 | 10.29 | |
Shareholders Equity per Share |
21.24 | 19.73 | 21.48 | 19.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.24 | 19.73 | 21.48 | 19.09 | |
Free Cash Flow |
(147.13) | (227.49) | (282.73) | (236.79) | |
Working Capital |
1,567.12 | 1,421.61 | 1,571.41 | 1,281.39 | |
Capital Expenditures |
(3.82) | (2.65) | (2.11) | (4.32) | |
Net Current Asset Value |
1,488.45 | 1,310.15 | 1,461.19 | 1,172.46 | |
| Other line items | |||||
Quick Ratio |
8.55 | 7.59 | 7.18 | 5.48 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.05) | (1.65) | (2.01) | (1.61) | |
Capex per Share |
(0.03) | (0.02) | (0.02) | (0.03) | |
Average Payables |
33.59 | 59.68 | 41.79 | 66.17 | |
Average Assets |
3,365.67 | 3,257.02 | 3,363.21 | 3,221.76 | |
Average Common Equity |
3,155.26 | 2,995.66 | 3,098.02 | 2,914.64 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates